Patrys Limited
Patrys Limited (PAB.AX) Stock Competitors & Peer Comparison
See (PAB.AX) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PAB.AX | A$0.03 | +0.00% | 10.9M | -1.60 | -A$0.02 | N/A |
| CSL.AX | A$141.03 | -0.01% | 68.4B | 16.27 | A$8.67 | +3.03% |
| TLX.AX | A$11.29 | +0.53% | 3.8B | -376.33 | -A$0.03 | N/A |
| MSB.AX | A$2.11 | -1.40% | 2.7B | -21.10 | -A$0.10 | N/A |
| NEU.AX | A$11.76 | -1.59% | 1.5B | 51.13 | A$0.23 | N/A |
| CU6.AX | A$3.83 | +1.06% | 1.4B | -13.68 | -A$0.28 | N/A |
| PYC.AX | A$1.42 | -2.41% | 825M | -17.69 | -A$0.08 | N/A |
| OPT.AX | A$0.60 | +0.00% | 820.8M | -1.40 | -A$0.43 | N/A |
| CUV.AX | A$9.93 | -1.97% | 498.3M | 15.52 | A$0.64 | +0.50% |
| RAC.AX | A$2.17 | -4.82% | 394.3M | -43.40 | -A$0.05 | N/A |
Stock Comparison
PAB.AX vs CSL.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, CSL.AX has a market cap of 68.4B. Regarding current trading prices, PAB.AX is priced at A$0.03, while CSL.AX trades at A$141.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas CSL.AX's P/E ratio is 16.27. In terms of profitability, PAB.AX's ROE is -4.06%, compared to CSL.AX's ROE of +0.08%. Regarding short-term risk, PAB.AX is less volatile compared to CSL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check CSL.AX's competition here
PAB.AX vs TLX.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, TLX.AX has a market cap of 3.8B. Regarding current trading prices, PAB.AX is priced at A$0.03, while TLX.AX trades at A$11.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas TLX.AX's P/E ratio is -376.33. In terms of profitability, PAB.AX's ROE is -4.06%, compared to TLX.AX's ROE of -0.02%. Regarding short-term risk, PAB.AX is less volatile compared to TLX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check TLX.AX's competition here
PAB.AX vs MSB.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, MSB.AX has a market cap of 2.7B. Regarding current trading prices, PAB.AX is priced at A$0.03, while MSB.AX trades at A$2.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas MSB.AX's P/E ratio is -21.10. In terms of profitability, PAB.AX's ROE is -4.06%, compared to MSB.AX's ROE of -0.18%. Regarding short-term risk, PAB.AX is less volatile compared to MSB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check MSB.AX's competition here
PAB.AX vs NEU.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, NEU.AX has a market cap of 1.5B. Regarding current trading prices, PAB.AX is priced at A$0.03, while NEU.AX trades at A$11.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas NEU.AX's P/E ratio is 51.13. In terms of profitability, PAB.AX's ROE is -4.06%, compared to NEU.AX's ROE of +0.09%. Regarding short-term risk, PAB.AX is less volatile compared to NEU.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check NEU.AX's competition here
PAB.AX vs CU6.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, CU6.AX has a market cap of 1.4B. Regarding current trading prices, PAB.AX is priced at A$0.03, while CU6.AX trades at A$3.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas CU6.AX's P/E ratio is -13.68. In terms of profitability, PAB.AX's ROE is -4.06%, compared to CU6.AX's ROE of -0.60%. Regarding short-term risk, PAB.AX is less volatile compared to CU6.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check CU6.AX's competition here
PAB.AX vs PYC.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, PYC.AX has a market cap of 825M. Regarding current trading prices, PAB.AX is priced at A$0.03, while PYC.AX trades at A$1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas PYC.AX's P/E ratio is -17.69. In terms of profitability, PAB.AX's ROE is -4.06%, compared to PYC.AX's ROE of -0.30%. Regarding short-term risk, PAB.AX is less volatile compared to PYC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check PYC.AX's competition here
PAB.AX vs OPT.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, OPT.AX has a market cap of 820.8M. Regarding current trading prices, PAB.AX is priced at A$0.03, while OPT.AX trades at A$0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas OPT.AX's P/E ratio is -1.40. In terms of profitability, PAB.AX's ROE is -4.06%, compared to OPT.AX's ROE of +1.32%. Regarding short-term risk, PAB.AX is less volatile compared to OPT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check OPT.AX's competition here
PAB.AX vs CUV.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, CUV.AX has a market cap of 498.3M. Regarding current trading prices, PAB.AX is priced at A$0.03, while CUV.AX trades at A$9.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas CUV.AX's P/E ratio is 15.52. In terms of profitability, PAB.AX's ROE is -4.06%, compared to CUV.AX's ROE of +0.13%. Regarding short-term risk, PAB.AX is less volatile compared to CUV.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check CUV.AX's competition here
PAB.AX vs RAC.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, RAC.AX has a market cap of 394.3M. Regarding current trading prices, PAB.AX is priced at A$0.03, while RAC.AX trades at A$2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas RAC.AX's P/E ratio is -43.40. In terms of profitability, PAB.AX's ROE is -4.06%, compared to RAC.AX's ROE of -0.47%. Regarding short-term risk, PAB.AX is less volatile compared to RAC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check RAC.AX's competition here
PAB.AX vs DXB.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, DXB.AX has a market cap of 210.1M. Regarding current trading prices, PAB.AX is priced at A$0.03, while DXB.AX trades at A$0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas DXB.AX's P/E ratio is -11.67. In terms of profitability, PAB.AX's ROE is -4.06%, compared to DXB.AX's ROE of -2.79%. Regarding short-term risk, PAB.AX is less volatile compared to DXB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check DXB.AX's competition here
PAB.AX vs OCC.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, OCC.AX has a market cap of 179.9M. Regarding current trading prices, PAB.AX is priced at A$0.03, while OCC.AX trades at A$0.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas OCC.AX's P/E ratio is -16.20. In terms of profitability, PAB.AX's ROE is -4.06%, compared to OCC.AX's ROE of -0.45%. Regarding short-term risk, PAB.AX is less volatile compared to OCC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check OCC.AX's competition here
PAB.AX vs SPL.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, SPL.AX has a market cap of 172.2M. Regarding current trading prices, PAB.AX is priced at A$0.03, while SPL.AX trades at A$0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas SPL.AX's P/E ratio is -41.00. In terms of profitability, PAB.AX's ROE is -4.06%, compared to SPL.AX's ROE of -0.16%. Regarding short-term risk, PAB.AX is less volatile compared to SPL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check SPL.AX's competition here
PAB.AX vs RCE.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, RCE.AX has a market cap of 137.4M. Regarding current trading prices, PAB.AX is priced at A$0.03, while RCE.AX trades at A$0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas RCE.AX's P/E ratio is -4.32. In terms of profitability, PAB.AX's ROE is -4.06%, compared to RCE.AX's ROE of +2.79%. Regarding short-term risk, PAB.AX is less volatile compared to RCE.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check RCE.AX's competition here
PAB.AX vs ACW.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, ACW.AX has a market cap of 132.3M. Regarding current trading prices, PAB.AX is priced at A$0.03, while ACW.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas ACW.AX's P/E ratio is -3.70. In terms of profitability, PAB.AX's ROE is -4.06%, compared to ACW.AX's ROE of -1.34%. Regarding short-term risk, PAB.AX is less volatile compared to ACW.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check ACW.AX's competition here
PAB.AX vs PAR.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, PAR.AX has a market cap of 114.2M. Regarding current trading prices, PAB.AX is priced at A$0.03, while PAR.AX trades at A$0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas PAR.AX's P/E ratio is -2.60. In terms of profitability, PAB.AX's ROE is -4.06%, compared to PAR.AX's ROE of -2.66%. Regarding short-term risk, PAB.AX is less volatile compared to PAR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check PAR.AX's competition here
PAB.AX vs ILA.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, ILA.AX has a market cap of 112.5M. Regarding current trading prices, PAB.AX is priced at A$0.03, while ILA.AX trades at A$0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas ILA.AX's P/E ratio is -15.00. In terms of profitability, PAB.AX's ROE is -4.06%, compared to ILA.AX's ROE of -1.01%. Regarding short-term risk, PAB.AX is less volatile compared to ILA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check ILA.AX's competition here
PAB.AX vs PAA.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, PAA.AX has a market cap of 111.9M. Regarding current trading prices, PAB.AX is priced at A$0.03, while PAA.AX trades at A$0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas PAA.AX's P/E ratio is -11.50. In terms of profitability, PAB.AX's ROE is -4.06%, compared to PAA.AX's ROE of -1.28%. Regarding short-term risk, PAB.AX is less volatile compared to PAA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check PAA.AX's competition here
PAB.AX vs BOT.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, BOT.AX has a market cap of 108.7M. Regarding current trading prices, PAB.AX is priced at A$0.03, while BOT.AX trades at A$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas BOT.AX's P/E ratio is -0.98. In terms of profitability, PAB.AX's ROE is -4.06%, compared to BOT.AX's ROE of -1.31%. Regarding short-term risk, PAB.AX is less volatile compared to BOT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check BOT.AX's competition here
PAB.AX vs NYR.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, NYR.AX has a market cap of 102.9M. Regarding current trading prices, PAB.AX is priced at A$0.03, while NYR.AX trades at A$0.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas NYR.AX's P/E ratio is -25.75. In terms of profitability, PAB.AX's ROE is -4.06%, compared to NYR.AX's ROE of -0.83%. Regarding short-term risk, PAB.AX is less volatile compared to NYR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check NYR.AX's competition here
PAB.AX vs ALA.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, ALA.AX has a market cap of 89.3M. Regarding current trading prices, PAB.AX is priced at A$0.03, while ALA.AX trades at A$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas ALA.AX's P/E ratio is -7.40. In terms of profitability, PAB.AX's ROE is -4.06%, compared to ALA.AX's ROE of -0.41%. Regarding short-term risk, PAB.AX is less volatile compared to ALA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check ALA.AX's competition here
PAB.AX vs ATH.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, ATH.AX has a market cap of 87M. Regarding current trading prices, PAB.AX is priced at A$0.03, while ATH.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas ATH.AX's P/E ratio is -0.80. In terms of profitability, PAB.AX's ROE is -4.06%, compared to ATH.AX's ROE of -0.30%. Regarding short-term risk, PAB.AX is less volatile compared to ATH.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check ATH.AX's competition here
PAB.AX vs BIO.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, BIO.AX has a market cap of 85.7M. Regarding current trading prices, PAB.AX is priced at A$0.03, while BIO.AX trades at A$0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas BIO.AX's P/E ratio is -38.50. In terms of profitability, PAB.AX's ROE is -4.06%, compared to BIO.AX's ROE of +0.18%. Regarding short-term risk, PAB.AX is less volatile compared to BIO.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check BIO.AX's competition here
PAB.AX vs CYP.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, CYP.AX has a market cap of 73.6M. Regarding current trading prices, PAB.AX is priced at A$0.03, while CYP.AX trades at A$0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas CYP.AX's P/E ratio is -7.75. In terms of profitability, PAB.AX's ROE is -4.06%, compared to CYP.AX's ROE of -1.79%. Regarding short-term risk, PAB.AX is less volatile compared to CYP.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check CYP.AX's competition here
PAB.AX vs NUZ.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, NUZ.AX has a market cap of 67.1M. Regarding current trading prices, PAB.AX is priced at A$0.03, while NUZ.AX trades at A$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas NUZ.AX's P/E ratio is -3.20. In terms of profitability, PAB.AX's ROE is -4.06%, compared to NUZ.AX's ROE of -2.54%. Regarding short-term risk, PAB.AX is less volatile compared to NUZ.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check NUZ.AX's competition here
PAB.AX vs IMM.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, IMM.AX has a market cap of 66.2M. Regarding current trading prices, PAB.AX is priced at A$0.03, while IMM.AX trades at A$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas IMM.AX's P/E ratio is -0.75. In terms of profitability, PAB.AX's ROE is -4.06%, compared to IMM.AX's ROE of -0.69%. Regarding short-term risk, PAB.AX is less volatile compared to IMM.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check IMM.AX's competition here
PAB.AX vs PTX.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, PTX.AX has a market cap of 61M. Regarding current trading prices, PAB.AX is priced at A$0.03, while PTX.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas PTX.AX's P/E ratio is -5.80. In terms of profitability, PAB.AX's ROE is -4.06%, compared to PTX.AX's ROE of -0.62%. Regarding short-term risk, PAB.AX is less volatile compared to PTX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check PTX.AX's competition here
PAB.AX vs IMU.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, IMU.AX has a market cap of 59.5M. Regarding current trading prices, PAB.AX is priced at A$0.03, while IMU.AX trades at A$0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas IMU.AX's P/E ratio is -0.80. In terms of profitability, PAB.AX's ROE is -4.06%, compared to IMU.AX's ROE of -1.35%. Regarding short-term risk, PAB.AX is less volatile compared to IMU.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check IMU.AX's competition here
PAB.AX vs ATX.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, ATX.AX has a market cap of 59M. Regarding current trading prices, PAB.AX is priced at A$0.03, while ATX.AX trades at A$0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas ATX.AX's P/E ratio is -5.75. In terms of profitability, PAB.AX's ROE is -4.06%, compared to ATX.AX's ROE of -0.25%. Regarding short-term risk, PAB.AX is less volatile compared to ATX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check ATX.AX's competition here
PAB.AX vs ENP.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, ENP.AX has a market cap of 55M. Regarding current trading prices, PAB.AX is priced at A$0.03, while ENP.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas ENP.AX's P/E ratio is N/A. In terms of profitability, PAB.AX's ROE is -4.06%, compared to ENP.AX's ROE of -1.05%. Regarding short-term risk, PAB.AX is less volatile compared to ENP.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check ENP.AX's competition here
PAB.AX vs PIQ.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, PIQ.AX has a market cap of 52.9M. Regarding current trading prices, PAB.AX is priced at A$0.03, while PIQ.AX trades at A$0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas PIQ.AX's P/E ratio is -4.57. In terms of profitability, PAB.AX's ROE is -4.06%, compared to PIQ.AX's ROE of -0.94%. Regarding short-term risk, PAB.AX is less volatile compared to PIQ.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check PIQ.AX's competition here
PAB.AX vs RAD.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, RAD.AX has a market cap of 52M. Regarding current trading prices, PAB.AX is priced at A$0.03, while RAD.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas RAD.AX's P/E ratio is -1.10. In terms of profitability, PAB.AX's ROE is -4.06%, compared to RAD.AX's ROE of -0.93%. Regarding short-term risk, PAB.AX is less volatile compared to RAD.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check RAD.AX's competition here
PAB.AX vs EZZ.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, EZZ.AX has a market cap of 48M. Regarding current trading prices, PAB.AX is priced at A$0.03, while EZZ.AX trades at A$1.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas EZZ.AX's P/E ratio is 17.00. In terms of profitability, PAB.AX's ROE is -4.06%, compared to EZZ.AX's ROE of +0.10%. Regarding short-term risk, PAB.AX is less volatile compared to EZZ.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check EZZ.AX's competition here
PAB.AX vs ADO.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, ADO.AX has a market cap of 35.7M. Regarding current trading prices, PAB.AX is priced at A$0.03, while ADO.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas ADO.AX's P/E ratio is -1.20. In terms of profitability, PAB.AX's ROE is -4.06%, compared to ADO.AX's ROE of -1.42%. Regarding short-term risk, PAB.AX is less volatile compared to ADO.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check ADO.AX's competition here
PAB.AX vs NSB.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, NSB.AX has a market cap of 30.9M. Regarding current trading prices, PAB.AX is priced at A$0.03, while NSB.AX trades at A$0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas NSB.AX's P/E ratio is -4.65. In terms of profitability, PAB.AX's ROE is -4.06%, compared to NSB.AX's ROE of -0.19%. Regarding short-term risk, PAB.AX is less volatile compared to NSB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check NSB.AX's competition here
PAB.AX vs AVE.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, AVE.AX has a market cap of 29.7M. Regarding current trading prices, PAB.AX is priced at A$0.03, while AVE.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas AVE.AX's P/E ratio is N/A. In terms of profitability, PAB.AX's ROE is -4.06%, compared to AVE.AX's ROE of -3.70%. Regarding short-term risk, PAB.AX is less volatile compared to AVE.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check AVE.AX's competition here
PAB.AX vs AGN.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, AGN.AX has a market cap of 28.3M. Regarding current trading prices, PAB.AX is priced at A$0.03, while AGN.AX trades at A$0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas AGN.AX's P/E ratio is -2.75. In terms of profitability, PAB.AX's ROE is -4.06%, compared to AGN.AX's ROE of -1.84%. Regarding short-term risk, PAB.AX and AGN.AX have similar daily volatility (0.00).Check AGN.AX's competition here
PAB.AX vs 1AI.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, 1AI.AX has a market cap of 25.7M. Regarding current trading prices, PAB.AX is priced at A$0.03, while 1AI.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas 1AI.AX's P/E ratio is N/A. In terms of profitability, PAB.AX's ROE is -4.06%, compared to 1AI.AX's ROE of -0.49%. Regarding short-term risk, PAB.AX is less volatile compared to 1AI.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check 1AI.AX's competition here
PAB.AX vs LCT.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, LCT.AX has a market cap of 24.5M. Regarding current trading prices, PAB.AX is priced at A$0.03, while LCT.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas LCT.AX's P/E ratio is N/A. In terms of profitability, PAB.AX's ROE is -4.06%, compared to LCT.AX's ROE of -0.62%. Regarding short-term risk, PAB.AX and LCT.AX have similar daily volatility (0.00).Check LCT.AX's competition here
PAB.AX vs NC6.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, NC6.AX has a market cap of 23.2M. Regarding current trading prices, PAB.AX is priced at A$0.03, while NC6.AX trades at A$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas NC6.AX's P/E ratio is -7.10. In terms of profitability, PAB.AX's ROE is -4.06%, compared to NC6.AX's ROE of -19.65%. Regarding short-term risk, PAB.AX is less volatile compared to NC6.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check NC6.AX's competition here
PAB.AX vs KZA.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, KZA.AX has a market cap of 18.9M. Regarding current trading prices, PAB.AX is priced at A$0.03, while KZA.AX trades at A$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas KZA.AX's P/E ratio is -0.73. In terms of profitability, PAB.AX's ROE is -4.06%, compared to KZA.AX's ROE of -26.34%. Regarding short-term risk, PAB.AX is less volatile compared to KZA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check KZA.AX's competition here
PAB.AX vs NOX.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, NOX.AX has a market cap of 18.7M. Regarding current trading prices, PAB.AX is priced at A$0.03, while NOX.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas NOX.AX's P/E ratio is -3.05. In terms of profitability, PAB.AX's ROE is -4.06%, compared to NOX.AX's ROE of +25.10%. Regarding short-term risk, PAB.AX is less volatile compared to NOX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check NOX.AX's competition here
PAB.AX vs BTC.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, BTC.AX has a market cap of 18.3M. Regarding current trading prices, PAB.AX is priced at A$0.03, while BTC.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas BTC.AX's P/E ratio is 5.90. In terms of profitability, PAB.AX's ROE is -4.06%, compared to BTC.AX's ROE of -0.10%. Regarding short-term risk, PAB.AX is less volatile compared to BTC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check BTC.AX's competition here
PAB.AX vs MEM.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, MEM.AX has a market cap of 15.7M. Regarding current trading prices, PAB.AX is priced at A$0.03, while MEM.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas MEM.AX's P/E ratio is N/A. In terms of profitability, PAB.AX's ROE is -4.06%, compared to MEM.AX's ROE of -0.92%. Regarding short-term risk, PAB.AX is less volatile compared to MEM.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check MEM.AX's competition here
PAB.AX vs MDC.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, MDC.AX has a market cap of 15.1M. Regarding current trading prices, PAB.AX is priced at A$0.03, while MDC.AX trades at A$6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas MDC.AX's P/E ratio is -0.01. In terms of profitability, PAB.AX's ROE is -4.06%, compared to MDC.AX's ROE of -9.94%. Regarding short-term risk, PAB.AX and MDC.AX have similar daily volatility (0.00).Check MDC.AX's competition here
PAB.AX vs BNO.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, BNO.AX has a market cap of 13.2M. Regarding current trading prices, PAB.AX is priced at A$0.03, while BNO.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas BNO.AX's P/E ratio is -0.45. In terms of profitability, PAB.AX's ROE is -4.06%, compared to BNO.AX's ROE of +0.45%. Regarding short-term risk, PAB.AX is less volatile compared to BNO.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check BNO.AX's competition here
PAB.AX vs CMB.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, CMB.AX has a market cap of 11M. Regarding current trading prices, PAB.AX is priced at A$0.03, while CMB.AX trades at A$0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas CMB.AX's P/E ratio is -3.43. In terms of profitability, PAB.AX's ROE is -4.06%, compared to CMB.AX's ROE of -2.19%. Regarding short-term risk, PAB.AX and CMB.AX have similar daily volatility (0.00).Check CMB.AX's competition here
PAB.AX vs BGT.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, BGT.AX has a market cap of 10.7M. Regarding current trading prices, PAB.AX is priced at A$0.03, while BGT.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas BGT.AX's P/E ratio is -3.50. In terms of profitability, PAB.AX's ROE is -4.06%, compared to BGT.AX's ROE of -1.40%. Regarding short-term risk, PAB.AX and BGT.AX have similar daily volatility (0.00).Check BGT.AX's competition here
PAB.AX vs TRP.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, TRP.AX has a market cap of 10.3M. Regarding current trading prices, PAB.AX is priced at A$0.03, while TRP.AX trades at A$0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas TRP.AX's P/E ratio is -2.83. In terms of profitability, PAB.AX's ROE is -4.06%, compared to TRP.AX's ROE of -0.30%. Regarding short-term risk, PAB.AX is less volatile compared to TRP.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check TRP.AX's competition here
PAB.AX vs CHM.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, CHM.AX has a market cap of 8.8M. Regarding current trading prices, PAB.AX is priced at A$0.03, while CHM.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas CHM.AX's P/E ratio is -0.20. In terms of profitability, PAB.AX's ROE is -4.06%, compared to CHM.AX's ROE of +28.45%. Regarding short-term risk, PAB.AX and CHM.AX have similar daily volatility (0.00).Check CHM.AX's competition here
PAB.AX vs IMC.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, IMC.AX has a market cap of 8M. Regarding current trading prices, PAB.AX is priced at A$0.03, while IMC.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas IMC.AX's P/E ratio is -1.55. In terms of profitability, PAB.AX's ROE is -4.06%, compared to IMC.AX's ROE of -0.44%. Regarding short-term risk, PAB.AX is less volatile compared to IMC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check IMC.AX's competition here
PAB.AX vs IXC.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, IXC.AX has a market cap of 7.9M. Regarding current trading prices, PAB.AX is priced at A$0.03, while IXC.AX trades at A$0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas IXC.AX's P/E ratio is -10.50. In terms of profitability, PAB.AX's ROE is -4.06%, compared to IXC.AX's ROE of -0.17%. Regarding short-term risk, PAB.AX and IXC.AX have similar daily volatility (0.00).Check IXC.AX's competition here
PAB.AX vs VBS.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, VBS.AX has a market cap of 6.9M. Regarding current trading prices, PAB.AX is priced at A$0.03, while VBS.AX trades at A$0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas VBS.AX's P/E ratio is -4.33. In terms of profitability, PAB.AX's ROE is -4.06%, compared to VBS.AX's ROE of +2.65%. Regarding short-term risk, PAB.AX is less volatile compared to VBS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check VBS.AX's competition here
PAB.AX vs ZLD.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, ZLD.AX has a market cap of 5.9M. Regarding current trading prices, PAB.AX is priced at A$0.03, while ZLD.AX trades at A$0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas ZLD.AX's P/E ratio is -1.56. In terms of profitability, PAB.AX's ROE is -4.06%, compared to ZLD.AX's ROE of +0.56%. Regarding short-term risk, PAB.AX is less volatile compared to ZLD.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check ZLD.AX's competition here
PAB.AX vs BIT.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, BIT.AX has a market cap of 4.9M. Regarding current trading prices, PAB.AX is priced at A$0.03, while BIT.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas BIT.AX's P/E ratio is -0.30. In terms of profitability, PAB.AX's ROE is -4.06%, compared to BIT.AX's ROE of -1.19%. Regarding short-term risk, PAB.AX is less volatile compared to BIT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check BIT.AX's competition here
PAB.AX vs ACR.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, ACR.AX has a market cap of 4.9M. Regarding current trading prices, PAB.AX is priced at A$0.03, while ACR.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas ACR.AX's P/E ratio is -1.20. In terms of profitability, PAB.AX's ROE is -4.06%, compared to ACR.AX's ROE of -2.12%. Regarding short-term risk, PAB.AX and ACR.AX have similar daily volatility (0.00).Check ACR.AX's competition here
PAB.AX vs RGS.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, RGS.AX has a market cap of 3.7M. Regarding current trading prices, PAB.AX is priced at A$0.03, while RGS.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas RGS.AX's P/E ratio is -1.20. In terms of profitability, PAB.AX's ROE is -4.06%, compared to RGS.AX's ROE of +4.56%. Regarding short-term risk, PAB.AX is less volatile compared to RGS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check RGS.AX's competition here
PAB.AX vs HXL.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, HXL.AX has a market cap of 2.2M. Regarding current trading prices, PAB.AX is priced at A$0.03, while HXL.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas HXL.AX's P/E ratio is -1.30. In terms of profitability, PAB.AX's ROE is -4.06%, compared to HXL.AX's ROE of -0.32%. Regarding short-term risk, PAB.AX and HXL.AX have similar daily volatility (0.00).Check HXL.AX's competition here
PAB.AX vs ANR.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, ANR.AX has a market cap of 2.1M. Regarding current trading prices, PAB.AX is priced at A$0.03, while ANR.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas ANR.AX's P/E ratio is -1.00. In terms of profitability, PAB.AX's ROE is -4.06%, compared to ANR.AX's ROE of -1.09%. Regarding short-term risk, PAB.AX and ANR.AX have similar daily volatility (0.00).Check ANR.AX's competition here
PAB.AX vs EX1.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, EX1.AX has a market cap of 1.9M. Regarding current trading prices, PAB.AX is priced at A$0.03, while EX1.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas EX1.AX's P/E ratio is -0.12. In terms of profitability, PAB.AX's ROE is -4.06%, compared to EX1.AX's ROE of -1.10%. Regarding short-term risk, PAB.AX and EX1.AX have similar daily volatility (0.00).Check EX1.AX's competition here
PAB.AX vs 1AD.AX Comparison March 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 10.9M. In comparison, 1AD.AX has a market cap of 522.2K. Regarding current trading prices, PAB.AX is priced at A$0.03, while 1AD.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -1.60, whereas 1AD.AX's P/E ratio is -0.40. In terms of profitability, PAB.AX's ROE is -4.06%, compared to 1AD.AX's ROE of +10.68%. Regarding short-term risk, PAB.AX is less volatile compared to 1AD.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check 1AD.AX's competition here